Diffuse Large B-Cell Lymphoma (DLBCL) is a type of non-Hodgkin lymphoma, which is a cancer of white blood cells that may present with an array of symptoms like fatigue, weight loss, and pain. Current first-line therapy for cancer treatment is chemotherapy, but the development of a more effective first-line treatment option is essential to improve long-term outcomes, particularly in high-risk patients.
Revive Research Institute is conducting a research study to find improved treatment modalities for DLBCL. This phase 3 trial is designed to compare the efficacy and safety of an immunotherapy and chemotherapy combination versus chemotherapy alone in previously untreated patients with newly-diagnosed DLBCL.
- Adults 18 years of age or older, male or female
- New diagnosis of diffuse large b-cell lymphoma, previously untreated
- Comply with study procedures
- Additional criteria may apply
Our group of licensed and certified physicians will be keeping track of the patient’s progress throughout the study and will address any concerns or queries that arise regarding the diffuse large b-cell lymphoma research trial. The investigational treatment is free for the duration of the clinical trial and insurance is not required. All patient records and information will be kept secure and confidential. The patient will also receive compensation for their time and involvement.